Healthcare
Halozyme Therapeutics, Inc.(HALO)
Live Price
Offline$68.55
-0.03% today
1Y Change
+31.30%
Window
Jun 27, 2025 โ Jun 18, 2026
- Market Cap
- $7.54B
- Revenue Growth
- +37.6%
- EPS Growth
- -24.6%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 27, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Halozyme Therapeutics, Inc. (HALO) is a Healthcare stock with a market cap of $7.54B and listed on NASDAQ. The stock last traded around $68.55 and up 31.3% across the available one-year price window (Jun 27, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +37.6%, EPS growth of -24.6%, a dividend yield of 0.0%. What stands out right now is revenue +37.6%, EPS -24.6%, free cash flow +37.6% with operating margin 58.4% and ROIC 23.6%. Valuation sits in the middle of the pack at P/E 23.6 and price/sales 5.4. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines HALO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+37.6% vs +7.6% peer median
Operating Margin
Above sector median
+58.4% vs +19.4% peer median
P/E
Below sector median
23.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +37.6% and EPS is at -24.6%, with operating margin around 58.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +0.7% | +7.7% | +6.0% |
2026 Feb 17, 2026 | -111.2% | -9.0% | -12.6% | -19.1% |
2025 Nov 3, 2025 | +5.5% | +2.8% | +2.7% | +0.5% |
Benchmark Edge
HALO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HALO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HALO Max Drawdown
-24.13%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HALO and SPY.
Company Overview
Halozyme Therapeutics, Inc.
NASDAQ Global Select
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
- Leadership
- Helen I. Torley
- IPO Date
- Mar 16, 2004
- Employees
- 350
- Street Address
- 11388 Sorrento Valley Road
- Mailing
- San Diego, CA, 92121
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 794 8889
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 23.6
- EV/EBITDA
- 7.7
- Price/Sales
- 5.4
- Price/Book
- 153.5
Growth
- Revenue
- +37.6%
- EPS
- -24.6%
- Free Cash Flow
- +37.6%
Profitability
- Gross Margin
- 81.9%
- Operating Margin
- 58.4%
- Net Margin
- 22.7%
- ROE
- 92.7%
- ROIC
- 23.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 4.66
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.